KKR’s approximately $5.7 billion agreement to acquire Integer Holdings Corporation is easy to describe as another healthcare buyout, but Integer’s position in the industry makes the transaction more revealing than that label suggests. Integer does not depend on one blockbuster consumer-facing medical device. It is one of the world’s larger medical-device contract development and manufacturing organisations, producing technologies and components used across cardiovascular, cardiac-rhythm-management and neuromodulation markets.
KKR agreed to pay $127 per Integer share in cash. The offer represented a 51.8% premium to Integer’s closing price on April 29, immediately before the company announced a strategic review, and a 28.8% premium to the 30-day volume-weighted average price through July 31. The transaction followed months of strategic scrutiny and is expected to close by the end of 2026, subject to shareholder and regulatory approvals.
The deal arrives amid a broader wave of private-capital activity in medtech. Blackstone and TPG completed their acquisition of women’s-health company Hologic in April 2026 in a transaction originally valued at up to $18.3 billion, while American Industrial Partners completed its approximately $1.27 billion acquisition of Avanos Medical in July.
Why buy Integer when its latest sales were not growing?
Integer reported second-quarter 2026 sales of $464.1 million, down 2.6% year over year, with organic sales down 1.5%. Cardio and vascular sales fell 2.3% to $280.3 million, while cardiac rhythm management and neuromodulation increased 1% to $173.7 million. Adjusted EBITDA declined 4.1% to $94.9 million.
Those figures do not resemble the type of explosive growth normally associated with a premium acquisition. They are also exactly why a private-equity thesis can differ from a public-market thesis. Public investors often penalise companies for temporary growth interruptions, customer product transitions or investments that depress near-term margins. A long-duration private owner may be more willing to absorb several quarters of uneven performance if the underlying market structure remains attractive.
KKR is acquiring Integer from its core private-equity strategy, which company materials describe as having an eight-to-ten-year or longer holding horizon. That is meaningful because the buyer does not necessarily need quarterly earnings acceleration immediately after closing.
The long-term attraction lies in Integer’s positioning inside customers’ development and manufacturing processes. Once a supplier is qualified for components incorporated into regulated medical devices, switching can require validation, engineering work, quality-system review and regulatory documentation. Those barriers can create durable relationships even when individual product volumes fluctuate.
Is outsourced medtech manufacturing becoming more strategically valuable?
Large medical-device companies increasingly need engineering capacity, specialised manufacturing processes and supply-chain resilience while simultaneously managing their own research, regulatory and commercial organisations. Outsourcing allows them to access expertise without owning every factory or technical capability internally.
Integer operates within that layer. Its products and services support cardiovascular devices, catheters, neuromodulation systems and cardiac-rhythm-management technologies, meaning its economic exposure can extend across multiple end markets rather than depending entirely on one branded product.
This creates an attractive private-capital characteristic: participation in healthcare innovation without having to choose the eventual winning finished device in every category. If multiple large manufacturers outsource more engineering or production, a scaled supplier can benefit across customers.
There are limits to that logic. Customer concentration can create pricing pressure, manufacturing problems can damage multiple programmes and new product transitions can temporarily reduce revenue, as Integer’s recent results demonstrate. But the underlying business can still possess valuable technical assets, skilled labour, regulated manufacturing sites and long-standing customer relationships.
Why does the purchase price look different depending on the reference point?
The $127 offer was only around 4.8% above Integer’s final unaffected trading price immediately before the transaction announcement, according to Reuters coverage, yet it represented a much larger premium to the stock price before the strategic review became public.
That difference illustrates how takeover speculation affects headline premiums. Once investors begin pricing a potential sale into a share price, comparing the final offer only with the previous trading day understates the value attributed to the transaction. KKR and Integer instead emphasised the 51.8% premium to the April 29 price and the 28.8% premium to the recent volume-weighted average.
For shareholders, the reference date influences how attractive the transaction appears. For KKR, the more important calculation is whether $5.7 billion represents a price from which operational improvements, organic growth, acquisitions and eventual exit value can generate an acceptable return over a long holding period.
Integer carried approximately $1.26 billion of principal debt and just over $21 million in cash at the end of the second quarter, according to company disclosures. That balance-sheet structure is relevant because the buyer is acquiring an enterprise with substantial existing leverage rather than an asset-light company with excess cash.
What do the Hologic and Avanos deals add to the picture?
The Hologic acquisition is much larger and strategically different. Blackstone and TPG took the women’s-health company private in a transaction valued at up to $79 per share, or up to $18.3 billion in enterprise value when announced. Hologic combines diagnostics, breast-health systems and surgical products rather than operating principally as a contract manufacturer.
Avanos Medical represents another model. American Industrial Partners completed its acquisition for approximately $1.272 billion, paying $25 per share and taking the medical-technology company private in July.
Putting the three transactions together does not mean private equity is following one identical medtech template. It shows instead that several characteristics of the sector remain attractive: recurring healthcare demand, established regulatory barriers, specialist manufacturing knowledge, strong installed relationships and the possibility of operational improvement away from quarterly public-market pressure.
Private owners can also pursue portfolio changes that may be uncomfortable in public markets, including factory consolidation, divestitures, acquisitions, pricing initiatives and multiyear margin programmes whose costs arrive before benefits.
Why could medtech CDMOs become consolidation targets?
Scale increasingly matters in medical-device manufacturing. Customers want suppliers capable of supporting engineering, quality, regulatory documentation, capacity expansion and production across several geographies. Smaller suppliers may possess strong niche capabilities but lack the balance sheet to invest quickly enough in automation or global manufacturing.
A private-equity owner can potentially use a platform such as Integer to acquire specialist businesses and combine them into a wider service offering. That creates opportunities for both revenue growth and cost efficiencies, although KKR has not committed publicly to any specific acquisition programme.
The model resembles consolidation seen in pharmaceutical contract manufacturing, where customers increasingly value suppliers that can handle larger portions of development and commercial production. Medtech differs technically and commercially, but the underlying attraction of becoming a larger, harder-to-replace outsourcing partner is similar.
What should medical-device companies watch after the KKR deal?
Customers will care first about continuity. Integer supplies components and finished technologies incorporated into regulated products, so changes in ownership cannot disrupt quality, capacity or delivery. KKR has emphasised continued investment in innovation and growth, but customers will judge the transaction through execution rather than financial messaging.
Competitors should watch capital spending and acquisitions. A privately owned Integer with access to KKR’s resources could accelerate capacity additions or pursue capabilities that broaden its role with major device manufacturers. Conversely, excessive leverage or aggressive cost reductions could undermine precisely the technical and service advantages that make the company valuable.
For the wider medtech industry, the deal adds another datapoint to a significant pattern. Blackstone and TPG bought Hologic, American Industrial Partners bought Avanos Medical, and KKR is now moving to acquire Integer Holdings. These are not identical assets, but private capital is repeatedly finding value in healthcare companies whose competitive advantages are built around regulated products, specialised infrastructure and durable customer relationships.
The most interesting part of KKR’s $5.7 billion wager may therefore be what it says about the less visible side of medtech. Investors naturally focus on the companies whose names appear on implants, scanners and diagnostic systems. Private equity appears increasingly interested in owning the platforms, factories and engineering capabilities that allow those products to exist in the first place.
